Skip to main content
. 2019 May 7;6(5):ofz214. doi: 10.1093/ofid/ofz214

Figure 2. .

Figure 2. 

A, Treatment outcomes for 8 weeks of treatment with sofosbuvir/ledipasvir without ribavirin for HCV genotype 1a and 1b in treatment-naïve, noncirrhotic patients. B, Treatment outcomes for 12 weeks of treatment with sofosbuvir/ledipasvir without ribavirin for HCV genotype 1a and 1b in treatment-naïve, noncirrhotic patients. P values are derived from Pearson’s chi-square test. Abbreviations: AE, adverse event; CI, confidence interval; Coinfected patients, HIV/HCV-coinfected patients; DC, treatment discontinuations (number [%]); HCV, hepatitis C virus; MoP, HCV-monoinfected patients.